See also this year's filing and all EDGAR filings for this company.
PDF Report 0001157601_2024_Madrigal_Pharmaceuticals_INC.pdf
Logs
| warning | Large missing amount for aggregate "Expenses" added to remainder. | industry.us_generic | {'missing_ratio': 0.6926359585766312, 'aggregate_val': 665558000, 'exp_sum': 393208000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 108146000, 'ResearchAndDevelopmentExpense': 272350000, 'remainder_Expenses': 12712000}} |
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'Revenues', 'net_inc_node': 'NetIncomeLoss'} |
Graph
Absolute values for 0001157601, Madrigal Pharmaceuticals INC
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 637,281,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 1,553,000 |
| 3 | remainder_Assets | 1,713,000 |
| 4 | LiabilitiesCurrent | 118,548,000 |
| 5 | LiabilitiesNoncurrent | 116,666,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 406,643,287 |
| 9 | ResearchAndDevelopmentExpense | 284,927,917 |
| 10 | remainder_Expenses | 292,407,295 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 31,300,433 |
| 13 | remainder_ComprehensiveNetIncome | 554,828 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 640,547,000 |
| 1 | Liabilities | 235,214,000 |
| 2 | Expenses | 983,978,499 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 405,333,000 |
| 5 | NetIncome | -952,678,066 |
| 6 | ComprehensiveNetIncome | -952,400,652 |
| 7 | BaseVar | 945,797,380 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -0.157 |
| 9 | EconomicCapitalRatio | 1.41 |
Edgar->Model Mapping
Feature Distribution
Change over Time
